Subheading · Chapter 30 · Heading 3003
3003.39: Other, containing hormones or other products of heading 2937: other
Other hormone medicines, bulk
Official description Other
3003.39 is the HS subheading for other hormone medicines, bulk, under heading 3003 in chapter 30.
What you pay
Importing into UK
Rates by national line · UK Global Tariff
UK lines →- 3003 39 00 00 Other Free
Additional duties and import rules
Charges on top of the customs duty, and rules the goods must meet at the border.
Import requirements 1
- Import controlRestriction on entry into free circulation
- Applies to goods from
- Ukraine
- Legal act
- S.I. 2022/395
- Documents
- 9009
- 9010
- 9017
Preferential rates by country
| Agreement or scheme | Countries | Rate |
|---|---|---|
| standard rate (no agreement) | — | Free |
| DCTS Comprehensive | Afghanistan, Angola, Bangladesh, Benin and 38 moreAfghanistan, Angola, Bangladesh, Benin, Bhutan, Burkina Faso, Burundi, Cambodia, Central African Republic, Chad, Comoros, Congo - Kinshasa, Djibouti, Eritrea, Ethiopia, Gambia, Guinea, Guinea-Bissau, Haiti, Kiribati, Laos, Liberia, Malawi, Mali, Mauritania, Myanmar (Burma), Nepal, Niger, Rwanda, São Tomé & Príncipe, Senegal, Sierra Leone, Somalia, South Sudan, Sudan, Tanzania, Timor-Leste, Togo, Tuvalu, Uganda, Yemen, Zambia | Free |
| European Union (including code "EU") | Free | |
| CARIFORUM | Antigua & Barbuda, Bahamas, Barbados, Belize and 10 moreAntigua & Barbuda, Bahamas, Barbados, Belize, Dominica, Dominican Republic, Grenada, Guyana, Jamaica, St Kitts & Nevis, St Lucia, St Vincent & the Grenadines, Suriname, Trinidad & Tobago | Free |
| OCTs (Overseas Countries and Territories) | Anguilla, Bermuda, British Indian Ocean Territory, British Virgin Islands and 7 moreAnguilla, Bermuda, British Indian Ocean Territory, British Virgin Islands, Cayman Islands, Falkland Islands, Montserrat, Pitcairn Islands, South Georgia & South Sandwich Islands, St Helena, Turks & Caicos Islands | Free |
| Central America | Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama | Free |
| SADC EPA | Botswana, Eswatini, Lesotho, Mozambique, Namibia | Free |
| Eastern and Southern Africa States | Madagascar, Mauritius, Seychelles, Zimbabwe | Free |
| CPTPP | Brunei, Malaysia | Free |
| UK–Andorra agreement | Andorra | Free |
| UK–Albania agreement | Albania | Free |
| UK–Australia agreement | Australia | Free |
| UK–Canada agreement | Canada | Free |
| UK–Switzerland agreement | Switzerland | Free |
| UK–Côte d’Ivoire agreement | Côte d’Ivoire | Free |
| UK–Chile agreement | Chile | Free |
| UK–Cameroon agreement | Cameroon | Free |
| UK–Colombia agreement | Colombia | Free |
| UK–Ceuta & Melilla agreement | Ceuta & Melilla | Free |
| UK–Ecuador agreement | Ecuador | Free |
| UK–Egypt agreement | Egypt | Free |
| UK–Fiji agreement | Fiji | Free |
| UK–Faroe Islands agreement | Faroe Islands | Free |
| UK–Georgia agreement | Georgia | Free |
| UK–Ghana agreement | Ghana | Free |
| UK–Israel agreement | Israel | Free |
| UK–India agreement | India | Free |
| UK–Iceland agreement | Iceland | Free |
| UK–Jordan agreement | Jordan | Free |
| UK–Japan agreement | Japan | Free |
| UK–Kenya agreement | Kenya | Free |
| UK–South Korea agreement | South Korea | Free |
| UK–Lebanon agreement | Lebanon | Free |
| UK–Liechtenstein agreement | Liechtenstein | Free |
| UK–Morocco agreement | Morocco | Free |
| UK–Moldova agreement | Moldova | Free |
| UK–North Macedonia agreement | North Macedonia | Free |
| UK–Mexico agreement | Mexico | Free |
| UK–Norway agreement | Norway | Free |
| UK–New Zealand agreement | New Zealand | Free |
| UK–Peru agreement | Peru | Free |
| UK–Papua New Guinea agreement | Papua New Guinea | Free |
| UK–Palestinian Territories agreement | Palestinian Territories | Free |
| UK–Serbia agreement | Serbia | Free |
| UK–Solomon Islands agreement | Solomon Islands | Free |
| UK–Singapore agreement | Singapore | Free |
| UK–San Marino agreement | San Marino | Free |
| UK–Tunisia agreement | Tunisia | Free |
| UK–Türkiye agreement | Türkiye | Free |
| UK–Ukraine agreement | Ukraine | Free |
| UK–Vietnam agreement | Vietnam | Free |
| UK–Samoa agreement | Samoa | Free |
| UK–Kosovo agreement | Kosovo | Free |
| UK–South Africa agreement | South Africa | Free |
UK: imports by month
Main suppliers, last 12 months
| Country | Value | Share | Change |
|---|---|---|---|
| £1.6m | 43.4% | +88.9% | |
| £1.2m | 33.4% | +75.1% | |
| £438k | 11.8% | -42.3% | |
| £314k | 8.4% | — | |
| £44k | 1.2% | -3% | |
| £30k | 0.8% | +68.9% | |
| £16k | 0.4% | -77.8% | |
| £6k | 0.2% | +109.7% |
Same subheading in other tariffs
World trade in 2024
Trade value (US$) no reported trade < US$236kUS$236k+US$8m+US$43m+> US$228m
Exports: 89
- Ireland: US$3bn
- United States: US$288m
- Denmark: US$228m
- Poland: US$91m
- Belgium: US$66m
- Netherlands: US$59m
- China: US$55m
- Germany: US$51m
- Kuwait: US$43m
- Spain: US$30m
- Pakistan: US$22m
- United Kingdom: US$22m
- France: US$21m
- Bulgaria: US$19m
- India: US$18m
- South Africa: US$18m
- Portugal: US$16m
- Italy: US$15m
- Greece: US$10m
- Canada: US$10m
- Czechia: US$9m
- Romania: US$8m
- Sweden: US$7m
- Indonesia: US$6m
- Austria: US$6m
- Switzerland: US$5m
- Hungary: US$5m
- Slovakia: US$5m
- Lithuania: US$4m
- Cyprus: US$4m
- Slovenia: US$3m
- Malta: US$2m
- Latvia: US$2m
- South Korea: US$2m
- Croatia: US$2m
- Australia: US$2m
- Japan: US$2m
- Kenya: US$1m
- Mexico: US$917k
- Israel: US$546k
- Colombia: US$471k
- Nigeria: US$431k
- Norway: US$338k
- Malaysia: US$236k
- Hong Kong SAR China: US$207k
- Finland: US$181k
- Türkiye: US$138k
- Argentina: US$107k
- Morocco: US$106k
- Thailand: US$92k
- Guatemala: US$83k
- Singapore: US$73k
- Brazil: US$67k
- Jordan: US$62k
- Taiwan: US$48k
- Vietnam: US$43k
- El Salvador: US$41k
- Eswatini: US$27k
- Luxembourg: US$26k
- Tunisia: US$19k
Trade value (US$) no reported trade < US$167kUS$167k+US$1m+US$12m+> US$75m
Imports: 188
- Belgium: US$3bn
- Denmark: US$325m
- United States: US$141m
- Germany: US$90m
- Netherlands: US$78m
- Poland: US$75m
- Ireland: US$62m
- India: US$33m
- Sweden: US$25m
- Norway: US$22m
- Japan: US$20m
- United Arab Emirates: US$18m
- Saudi Arabia: US$15m
- Switzerland: US$15m
- Afghanistan: US$14m
- Lithuania: US$13m
- Canada: US$13m
- Italy: US$13m
- Bulgaria: US$12m
- France: US$11m
- Brazil: US$11m
- Austria: US$9m
- Spain: US$9m
- Hungary: US$8m
- China: US$7m
- Qatar: US$7m
- Nigeria: US$6m
- Finland: US$5m
- Iraq: US$5m
- Türkiye: US$5m
- Portugal: US$5m
- Kuwait: US$3m
- Malaysia: US$3m
- Tunisia: US$3m
- Czechia: US$3m
- Oman: US$3m
- United Kingdom: US$2m
- Bahrain: US$2m
- Argentina: US$2m
- Cyprus: US$2m
- Zambia: US$2m
- Mexico: US$2m
- Pakistan: US$2m
- Romania: US$2m
- Croatia: US$2m
- Uzbekistan: US$2m
- Egypt: US$1m
- Singapore: US$1m
- Indonesia: US$1m
- Philippines: US$1m
- Slovakia: US$1m
- Sudan: US$1m
- Algeria: US$1m
- Australia: US$1m
- Myanmar (Burma): US$967k
- Ukraine: US$930k
- Latvia: US$899k
- Greece: US$891k
- Bahamas: US$860k
- Lesotho: US$839k
Top exporters
| Rank | Country | Value | Share |
|---|---|---|---|
| 1 | US$3bn | 70.9% | |
| 2 | US$288m | 7.2% | |
| 3 | US$228m | 5.7% | |
| 4 | US$91m | 2.3% | |
| 5 | US$66m | 1.7% | |
| 6 | US$59m | 1.5% | |
| 7 | US$55m | 1.4% | |
| 8 | US$51m | 1.3% | |
| 9 | US$43m | 1.1% | |
| 10 | US$30m | 0.8% |
Top importers
| Rank | Country | Value | Share |
|---|---|---|---|
| 1 | US$3bn | 70.7% | |
| 2 | US$325m | 8.1% | |
| 3 | US$141m | 3.5% | |
| 4 | US$90m | 2.2% | |
| 5 | US$78m | 2% | |
| 6 | US$75m | 1.9% | |
| 7 | US$62m | 1.5% | |
| 8 | US$33m | 0.8% | |
| 9 | US$25m | 0.6% | |
| 10 | US$22m | 0.5% |
Import duty on this product around the world 165
The most-favoured-nation (MFN) duty each country applies to goods of this HS subheading: the average over its national tariff lines, with the lowest and highest line where they differ. Goods from countries with a trade agreement often pay less.
- 0%median duty
- 112number of duty-free countries (MFN)
- 20%highest: Montserrat, Iran, French Polynesia
165
| Importing country | MFN duty | lines from – to | data year |
|---|---|---|---|
| 2.5% | 2018 · HS 2012 | ||
| 0% | 2023 | ||
| 5% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2021 · HS 2017 | ||
| 0% | 2021 · HS 2007 | ||
| 7.3% | 0% – 14% | 2023 · HS 2017 | |
| 0% | 2023 | ||
| 6% | 2021 · HS 2012 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2022 | ||
| 0% | 2023 | ||
| 2.5% | 0% – 5% | 2023 · HS 2017 | |
| 0% | 2022 · HS 2017 | ||
| 0% | 2021 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2022 | ||
| 5% | 2023 · HS 2017 | ||
| 0% | 2022 | ||
| 0% | 2023 | ||
| 7.3% | 0% – 14% | 2023 · HS 2017 | |
| 0% | 2023 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 5% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 12% | 2021 · HS 2002 | ||
| 5% | 2023 | ||
| 5% | 2023 | ||
| 6% | 2023 · HS 2017 | ||
| 0% | 2023 | ||
| 5% | 2023 · HS 2017 | ||
| 0% | 2021 · HS 2017 | ||
| 5% | 2023 | ||
| 0% | 2022 · HS 2017 | ||
| 2.5% | 0% – 5% | 2023 | |
| 0% | 2023 · HS 2017 | ||
| 1% | 2023 · HS 2017 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2023 | ||
| 5% | 2023 · HS 2017 | ||
| 1% | 0% – 2% | 2019 · HS 2017 | |
| 0% | 2022 | ||
| 5% | 2023 | ||
| 0% | 2023 | ||
| 5% | 2021 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 15% | 2023 | ||
| 5% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2022 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2023 · HS 2012 | ||
| 5% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2020 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 10% | 2023 | ||
| 5% | 2023 | ||
| 16% | 5% – 26% | 2020 · HS 2017 | |
| 6% | 0% – 12% | 2022 · HS 2017 | |
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2002 | ||
| 0% | 2023 | ||
| 0% | 2021 · HS 2017 | ||
| 10% | 2023 · HS 2017 | ||
| 5% | 2020 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2021 · HS 2017 | ||
| 0% | 2021 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2021 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2023 | ||
| 5% | 0% – 10% | 2023 · HS 2017 | |
| 4% | 2021 · HS 2017 | ||
| 0% | 2023 · HS 2017 | ||
| 5% | 2023 | ||
| 20% | 2023 · HS 2017 | ||
| 10% | 2.5% – 18% | 2023 | |
| 0% | 2023 | ||
| 1.5% | 2023 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2021 · HS 2017 | ||
| 15% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 11% | 2023 | ||
| 0% | 2023 · HS 2012 | ||
| 6% | 0% – 12% | 2017 · HS 2017 | |
| 0% | 2023 | ||
| 0% | 2023 | ||
| 7.3% | 0% – 14% | 2023 · HS 2017 | |
| 0% | 2023 · HS 2017 | ||
| 3% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2021 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2020 · HS 2017 | ||
| 5% | 2019 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 5% | 2023 · HS 2017 | ||
| 5% | 2023 · HS 2017 | ||
| 0% | 2023 | ||
| 8% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2012 | ||
| 5% | 2021 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2021 · HS 2017 | ||
| 0% | 2023 · HS 2007 | ||
| 0% | 2023 | ||
| 1% | 2020 · HS 2012 | ||
| 5% | 2021 · HS 2012 | ||
| 0% | 2023 | ||
| 10% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2023 · HS 2012 | ||
| 0% | 2023 | ||
| 0% | 2017 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 7.3% | 0% – 14% | 2023 · HS 2017 | |
| 0% | 2021 · HS 2017 | ||
| 0% | 2023 | ||
| 7.3% | 0% – 14% | 2023 · HS 2017 | |
| 0% | 2023 | ||
| 4% | 2021 · HS 2012 | ||
| 5% | 2017 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 0% – 0.1% | 2023 |
Tariff data years 2017–2023; rates may have changed since. · UNCTAD TRAINS, accessed via WITS (World Bank)
Classifications and correspondences
Where this HS subheading sits in the United Nations' statistical classifications, and which codes it had in earlier editions of the Harmonized System.
- SITC Rev. 4
- 54222 Medicaments containing other hormones/other products of subgroup 541.5, not put up in measured doses/in forms/packings for retail sale
- End use (BEC Rev. 5)
- Intermediate goods · BEC 711220
- CPC 2.1 product
- 35260 Medicaments, for therapeutic or prophylactic uses
- ISIC Rev. 4 activity
- 2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products
Earlier HS editions
| HS | Code | |
|---|---|---|
| 2017 | 3003.39 | unchanged |
| 2012 | 3003.39 | unchanged |
| 2007 | 3003.39 | unchanged |
| 2002 | 3003.39 | unchanged |
| 1996 | 3003.39 | changed |
| 1992 | 3003.39 | changed |
Correspondence tables of the United Nations Statistics Division (UNSD)
Recent rule changes mentioning this code
Acts whose text cites this code or its heading. Check the act itself: a code can be cited for reasons other than a change of its duty.
-
FR Doc. 2026-19498 · 91 FR 60360 · Source: federalregister.gov
-
FR Doc. 2026-14542 · 91 FR 45516 · Source: federalregister.gov
-
FR Doc. 2026-11158 · 91 FR 33854 · Source: federalregister.gov
The UK Global Tariff has one tariff line for subheading 3003.39; the duty is duty-free.
Subheading 3003.39 is a single line in the EU Combined Nomenclature, where the duty is duty-free.
156 countries pay no duty in the UK thanks to trade agreements and preference schemes such as DCTS Comprehensive and European Union, against a standard rate of Free.
Imports of other hormone medicines, bulk into the UK came to £3.7m between September 2025 and August 2026 (up 19% on the year before); France supplied 43%, followed by Sweden.
In 2024, countries exported other hormone medicines, bulk worth US$4bn (+9.4% year on year).
The largest exporter was Ireland (US$3bn), followed by the United States.
Questions and answers
What is the HS code for other, containing hormones or other products of heading 2937: other?
Other, containing hormones or other products of heading 2937: other fall under HS subheading 3003.39, part of heading 3003, in section VI of the Harmonized System.
What is the import duty on other, containing hormones or other products of… in the UK?
Under the UK Global Tariff, imports under 3003.39 from countries without a preferential agreement are free of duty. Preferential rates, anti-dumping duties and VAT are not included.
What is the import duty on other, containing hormones or other products of… in the EU?
Under the EU Combined Nomenclature, imports under 3003.39 from countries without a preferential agreement are free of duty. Preferential rates, anti-dumping duties and VAT are not included.
Which country exports the most other, containing hormones or other products of…?
Ireland, with US$3bn in 2024 (70.9% of world exports).
Which countries can export other hormone medicines, bulk to the UK duty-free?
156 countries pay no duty under a trade agreement or preference scheme, among them partners under DCTS Comprehensive, European Union, CARIFORUM. The goods must meet the agreement’s rules of origin and the importer needs proof of origin; otherwise the standard rate of Free applies. Pick a country above to see its rate.
Where does the UK import other hormone medicines, bulk from?
In the 12 months to August 2026, the largest suppliers were France (43%), Sweden (33%) and Greece (12%), out of total imports of £3.7m.